Craig-Hallum analyst John Wilkin initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $15 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies Holds Annual Shareholders Meeting
- Adaptive Biotechnologies highlights new data at ASCO Meeting, EHA Congress
- Adaptive Biotechnologies price target raised to $13 from $11 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Adaptive Biotechnologies price target raised to $9 from $7 at Morgan Stanley